[Chemotherapy of bronchopulmonary and pleural adenocarcinoma. Apropos of 31 cases].
Between January 1978 and June 1983, 31 patients aged between 35 and 73 years, with an adenocarcinoma of the respiratory system (25 lung cancers and 6 pleural cancers) were treated by chemotherapy, either exclusively or following failure of surgery. In 21 patients, the treatment consisted of a combination of cyclo-phosphamide (600 mg/m2), adriamycin (40 mg/m2) and 5-fluoro-uracil (600 mg/m2) by intravenous injection, every four weeks. The other 10 patients received different treatments, but platinum salts were administered in only 2 cases. The treatment was fairly well tolerated (only 1 death due to toxicity), but the effectiveness remained disappointing: only 1 complete response (alive after 48 months), 2 partial responses and 4 stabilisations. The overall median survival was 9 months, with a mean survival of 11.6 months. The mean survival of the responder and stabilised patients was more than 21 months. These results lead us to recommend that, apart from randomised trials, chemotherapy should be stopped after the second course in the absence of at least a stabilisation of the disease, in which prolonged survivals are sometimes observed when treatment is limited to purely symptomatic measures.